Profile data is unavailable for this security.
About the company
Xvivo Perfusion AB is a Sweden-based medical technology company focused on developing optimized solutions for organ, tissue and cell preservation in connection with transplantation. The Company operates in two segments: Durable goods and Non-Durable goods. The Durable goods segment comprises sale and rental income from XVIVO Perfusion System (XPS) machines. The Non-Durable goods segment implies revenue from the sale of products and services that are solutions and disposable items. The Company’s product portfolio consists of Perfadex, STEEN Solution, XPS, XPS Disposable Kit, XVIVO Lung Cannula Set, XVIVO Organ Chamber, XPS PGM Disposable Sensors and Silicone Tubing Set. The Company markets its products in Europe, Asia, Middle East, and North & South America.
- Revenue in SEK (TTM)597.54m
- Net income in SEK91.82m
- Incorporated1998
- Employees160.00
- LocationXvivo Perfusion ABMassans gata 10GOETEBORG 412 51SwedenSWE
- Phone+46 317882150
- Fax+46 317882169
- Websitehttps://www.xvivoperfusion.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Bactiguard Holding AB | 223.17m | -138.38m | 2.11bn | 217.00 | -- | 6.75 | -- | 9.46 | -3.95 | -3.95 | 6.37 | 10.08 | 0.3037 | 4.37 | 6.93 | 1,028,447.00 | -18.83 | -7.56 | -24.62 | -8.81 | 27.47 | 47.91 | -62.01 | -26.28 | 0.6445 | -8.67 | 0.3976 | -- | -11.96 | 6.46 | -161.71 | -- | 8.43 | -- |
| Detection Technology Oyj | -1.16tn | -1.16tn | 2.29bn | 478.00 | -- | 2.71 | -- | -- | -- | -- | -- | 4.97 | -- | -- | -- | -- | -- | 9.34 | -- | 11.96 | -- | 47.44 | -- | 8.22 | 3.13 | -- | 0.081 | 53.45 | 5.29 | 2.02 | 7.55 | -18.03 | -14.88 | -9.55 |
| Medistim ASA | 521.52m | 102.87m | 3.20bn | 152.00 | 31.01 | 8.09 | 25.32 | 6.13 | 5.68 | 5.68 | 28.77 | 21.77 | 1.07 | 0.8646 | 5.98 | 3,462,921.00 | 21.01 | 22.93 | 26.14 | 28.52 | 78.67 | 78.25 | 19.72 | 20.64 | 2.61 | -- | 0.0425 | 75.25 | 7.00 | 10.06 | -8.91 | 12.72 | 0.033 | 14.87 |
| BICO Group AB | 2.25bn | -1.70bn | 3.24bn | 884.00 | -- | 0.6788 | -- | 1.44 | -23.61 | -27.66 | 31.60 | 69.18 | 0.2487 | 2.24 | 3.06 | 2,545,136.00 | -18.77 | -- | -20.89 | -- | 52.34 | -- | -75.47 | -- | 1.91 | -1.05 | 0.2852 | -- | 6.09 | -- | -1,889.33 | -- | -- | -- |
| CellaVision AB | 677.29m | 130.31m | 5.56bn | 228.00 | 42.65 | 7.76 | 32.68 | 8.21 | 5.46 | 5.46 | 28.40 | 30.04 | 0.7441 | 1.60 | 6.93 | 2,970,575.00 | 14.32 | 15.30 | 16.62 | 18.24 | 68.37 | 69.03 | 19.24 | 19.98 | 2.01 | 59.03 | 0.0828 | 110.18 | 5.94 | 13.17 | 10.12 | 8.00 | 30.45 | 8.45 |
| Revenio Group Oyj | 1.12bn | 220.52m | 7.67bn | 216.00 | 34.39 | 6.60 | 28.80 | 6.84 | 0.7205 | 0.7205 | 3.66 | 3.76 | 0.7069 | 5.50 | 7.60 | 447,574.10 | 13.90 | 14.33 | 16.77 | 17.90 | 51.01 | 50.73 | 19.66 | 21.13 | 1.79 | 28.49 | 0.1521 | 55.81 | -0.4125 | 25.80 | -12.15 | 18.72 | 17.67 | 6.30 |
| Synsam AB (publ) | 5.91bn | 311.00m | 7.76bn | 3.41k | 24.78 | 3.05 | 7.35 | 1.31 | 2.09 | 2.09 | 39.62 | 16.96 | 0.7356 | 2.22 | 13.12 | 1,730,149.00 | 3.86 | -- | 5.27 | -- | 75.50 | -- | 5.25 | -- | 0.4922 | -- | 0.5675 | -- | 11.90 | -- | -5.18 | -- | -- | -- |
| Xvivo Perfusion AB | 597.54m | 91.82m | 9.89bn | 160.00 | 102.32 | 5.09 | 65.19 | 16.55 | 3.07 | 3.07 | 19.95 | 61.75 | 0.3042 | 1.23 | 6.20 | 3,734,638.00 | 4.67 | 1.23 | 5.02 | 1.33 | 74.49 | 73.14 | 15.37 | 4.76 | 5.09 | -- | 0.0159 | 0.00 | 43.88 | 26.04 | 398.29 | 48.57 | 21.35 | -- |
| Arjo AB (publ) | 11.10bn | 518.00m | 12.21bn | 6.71k | 25.26 | 1.62 | 7.88 | 1.10 | 1.90 | 1.90 | 40.76 | 29.72 | 0.6911 | 4.15 | 6.31 | 1,632,980.00 | 3.21 | 3.55 | 4.44 | 5.55 | 43.43 | 44.01 | 4.64 | 5.41 | 0.6913 | 4.14 | 0.4024 | 43.01 | 10.03 | 5.97 | 6.90 | 10.15 | -8.89 | 10.35 |
| Biotage AB | 1.86bn | 246.00m | 12.80bn | 674.00 | 49.26 | 3.50 | 32.57 | 6.88 | 3.25 | 3.25 | 25.16 | 45.71 | 0.5122 | 1.92 | 6.85 | 2,762,611.00 | 6.77 | 10.74 | 8.00 | 12.77 | 61.71 | 61.34 | 13.21 | 15.77 | 1.43 | 32.64 | 0.0661 | 40.11 | 18.90 | 15.37 | -8.21 | 7.97 | 14.05 | 1.30 |
| Embla Medical hf | 8.55bn | 635.69m | 20.01bn | 4.00k | 31.05 | 2.57 | 16.91 | 2.34 | 0.9694 | 0.9694 | 13.11 | 11.69 | 0.5796 | 2.24 | 6.54 | 1,375,680.00 | 4.34 | 4.06 | 5.17 | 4.76 | 61.80 | 62.47 | 7.48 | 6.91 | 1.22 | 6.68 | 0.3988 | 3.99 | 9.33 | 5.09 | 37.34 | -6.05 | 6.50 | -- |
| Elekta AB (publ) | 18.22bn | 1.43bn | 28.01bn | 4.58k | 20.31 | 2.83 | 11.06 | 1.54 | 3.74 | 3.74 | 47.60 | 26.82 | 0.6208 | 3.29 | 2.90 | 4,150,570.00 | 4.89 | 4.32 | 8.69 | 7.89 | 37.90 | 39.93 | 7.88 | 7.68 | 0.8219 | 4.02 | 0.4106 | 65.79 | 15.95 | 7.83 | -18.28 | -6.90 | 12.86 | 11.38 |
Data as of Apr 23 2024. Currency figures normalised to Xvivo Perfusion AB's reporting currency: Swedish Krona SEK
35.58%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Swedbank Robur Fonder ABas of 31 Dec 2022 | 2.90m | 9.20% |
| Fj�rde AP-fondenas of 31 Dec 2022 | 2.74m | 8.68% |
| Premier Fund Managers Ltd.as of 31 Dec 2022 | 1.16m | 3.68% |
| Invesco Advisers, Inc.as of 31 Dec 2022 | 1.02m | 3.23% |
| Capital Research & Management Co. (World Investors)as of 31 Mar 2024 | 875.63k | 2.78% |
| Handelsbanken Fonder ABas of 31 Dec 2022 | 814.41k | 2.59% |
| Deka Investment GmbHas of 31 Dec 2022 | 499.14k | 1.59% |
| Andra AP-fondenas of 31 Dec 2022 | 443.26k | 1.41% |
| Tredje AP-fondenas of 28 Nov 2022 | 425.85k | 1.35% |
| Joh. Berenberg, Gossler & Co. KG (Investment Management)as of 30 Dec 2022 | 341.82k | 1.09% |
More ▼
Data from 31 Dec 2023 - 31 Mar 2024Source: FactSet Research Systems Inc.
